Ventric Health

What Ventric Health does

Ventric Health (DBA of Avicena, LLC) is a Pasadena, California-based medical device company that has developed the Vivio System, an FDA-cleared Class II medical device that non-invasively measures left ventricular end-diastolic pressure (LVEDP), the clinical hallmark of heart failure. The system uses physics-based hemodynamic algorithms, derived from more than 15 years of Caltech research, that analyze cardiac waveforms captured via a single-lead ECG patch and a pneumatic arm cuff to estimate LVEDP in under five minutes at the point of care. Once a positive result is generated, the system prompts administration of the KCCQ-12 questionnaire to quantify symptom burden and stage disease severity, supporting guideline-directed medical therapy initiation in primary care.

The company has received FDA 510(k) clearance (October 2023), peer-reviewed multicenter validation in JAHA (80% sensitivity, 83% specificity) and a real-world efficacy study in JACC Advances, and has performed nearly 30,000 cumulative tests across U.S. health system partners including Agilon Health, AltaMed, Desert Oasis Healthcare, Heritage Victor Valley Medical Group and Regal Medical Group. The product is sold on a per conclusive test basis, with equipment, training and support included in the licensing agreement and snap electrodes as the recurring consumable; no prior authorization or patient cost is required.

Ventric Health targets value-based care buyers, including primary care physician groups, Medicare ACOs, Medicare Advantage plans, healthcare systems and Medicare practice aggregators, with an enterprise field sales motion supported by personalized live demonstrations, clinical evidence marketing, and an in-house commercial team including a former UnitedHealthcare growth executive. Operations are U.S.-only and the company holds SOC 2, HIPAA, NIST, HITRUST e1 and ISO 27001-aligned certifications, with EHR integration via Redox.

Name

Ventric Health

Legal name

Avicena, LLC

Website

https://ventrichealth.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Ventric Health (DBA Avicena, LLC) sells the FDA-cleared Vivio System, a non-invasive Class II medical device that measures left ventricular end-diastolic pressure in primary care to enable earlier heart failure diagnosis for value-based care buyers including ACOs, Medicare Advantage plans and health systems.

Ownership category

akta.pro rank

Product category

Cardiovascular Diagnostic Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Home Health Care Services (62161)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT) (HLAHAFAI)

akta.pro secondary industries

Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity) (HLALAFAA), Chronic Disease Management Pathways (e.g., diabetes, CHF, COPD) (HLACAGAG), Home Cardiac Care & Remote Patient Monitoring (Skilled Oversight) (HLADAFAJ), Cardiology Telemedicine Platforms (HLALAGAB)

Keywords

• Cardiovascular diagnostic devices
• Heart failure detection
• Non-invasive hemodynamic monitoring
• Point-of-care medical devices
• LVEDP measurement systems

Headquarters

HQ city

Pasadena

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Per Conclusive Test Licensing: The Vivio System is billed on a per conclusive test basis with all equipment, training, and support included. Equipment (Vivio hardware and iPad) is provided as part of the licensing agreement. Customers are responsible for purchasing additional snap electrodes on an ongoing basis. Pilot sites can generally be activated in 4-6 weeks after initiating the implementation process.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

Ventric Health sells the Vivio System, an FDA-cleared Class II medical device that enables clinicians to non-invasively measure left ventricular end-diastolic pressure (LVEDP), the clinical hallmark of heart failure, at the point of care in under five minutes. The system uses physics-based hemodynamic algorithms applied to cardiac waveforms captured via a pneumatic arm cuff and single-lead ECG patch, and integrates the KCCQ-12 questionnaire to quantify heart failure symptom burden. Customers license the device on a per conclusive test basis, with hardware, iPad, training, and support bundled into the agreement.

Product overview

Ventric Health offers a single unified product—the Vivio System—which is an FDA-cleared non-invasive medical device for heart failure detection. The Vivio System comprises the core diagnostic device (hardware with arm cuff, EKG patch, and tablet interface running proprietary physics-based algorithms) plus the integrated KCCQ-12 symptom assessment questionnaire. Together, these components enable point-of-care detection of elevated left ventricular end-diastolic pressure (LVEDP) and patient-reported symptom quantification to support guideline-directed medical therapy initiation in primary care settings.

Differentiator

Problem solved

Functional benefit

Brands

• Vivio System: FDA-cleared Class II medical device for non-invasive measurement of left ventricular end-diastolic pressure (LVEDP) to detect heart failure in primary care settings.

Products and services

• Vivio System The Vivio System is an FDA-cleared Class II medical device that non-invasively measures left ventricular end-diastolic pressure (LVEDP) in under five minutes at the point of care using physics-based hemodynamic analysis of cardiac waveforms and ECG signals. It is licensed to primary care clinicians, healthcare systems, Medicare ACOs, and Medicare Advantage plans on a per conclusive test basis, with hardware, iPad, training, and support bundled.

Quantifiable outcome

• 80% sensitivity and 83% specificity for elevated LVEDP detection
• +9 more outcomes

Named customers7 records

Segments6 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability2 records

Feature4 records

Partnerships

Six partnerships are on record, tiered core and flagship.

• RedoxcoreTechnology or IntegrationVentric Health offers Vivio-EHR integration package through Redox, a commercial intermediary platform specializing in EHR integration. Redox supports posting Vivio results to the EHR encounter, as well as matching MRN/DOB and pulling patient name into Vivio from the EHR.
• Agilon HealthflagshipOthersHealth system partner implementing the Vivio System across their network for earlier heart failure detection in primary care settings. Part of a select group of health systems using Vivio across the country.
• AltaMedflagshipOthersHealth system partner implementing the Vivio System across their network for earlier heart failure detection in primary care settings.
• Desert Oasis HealthcareflagshipOthersHealth system partner that adopted Vivio System in March 2024. Desert Oasis Healthcare has successfully integrated Vivio into their primary care strategy, enabling earlier identification of heart function changes and more timely treatment initiation.
• Heritage Victor Valley Medical GroupflagshipOthersHealth system partner implementing the Vivio System across their network for earlier heart failure detection in primary care settings.
• Regal Medical GroupflagshipOthersHealth system partner implementing the Vivio System across their network for earlier heart failure detection in primary care settings.

Scale indicators11 records

Recent moves5 records

Expansion highlights6 records

Direct peers

• HeartFlow: HeartFlow provides non-invasive, image-based coronary diagnostics for heart disease, similar to how Vivio provides non-invasive hemodynamic diagnostics. Both companies target cardiovascular disease diagnosis in outpatient settings using novel non-invasive technologies validated against gold-standard invasive measurements.
• Eko Health: Eko Health offers AI-enabled digital stethoscopes and cardiac detection algorithms for use in primary care and ambulatory settings. Both Eko and Ventric Health bring advanced, non-invasive cardiovascular diagnostics into the primary care visit with a focus on earlier detection of cardiac conditions.
• AliveCor: AliveCor's KardiaMobile is a consumer- and clinician-facing single-lead ECG device for cardiac arrhythmia detection. Both companies offer compact, non-invasive point-of-care cardiac diagnostics that integrate into primary care workflows and pair with digital health platforms.

Emerging players

• iRhythm Technologies: iRhythm provides wearable, non-invasive cardiac monitoring (Zio) for arrhythmia detection, often used in primary care and cardiology referrals. Both companies address the underdiagnosis of cardiac conditions via continuous or point-of-care non-invasive monitoring, though iRhythm focuses on rhythm disorders rather than hemodynamic pressure measurement.
• Cleerly: Cleerly applies AI to coronary CT angiography to non-invasively characterize coronary plaque and diagnose coronary artery disease. Like Ventric Health, Cleerly is a non-invasive cardiac diagnostics company targeting earlier detection of cardiovascular disease in outpatient care settings.
• Us2.ai: Us2.ai offers AI-driven automated echocardiography analysis for heart failure and cardiac disease diagnosis. Both companies apply novel computational approaches to non-invasively detect heart failure earlier, though Us2.ai uses imaging AI while Vivio uses physics-based hemodynamic analysis.

Broad incumbents

• Edwards Lifesciences: Edwards is a global leader in hemodynamic monitoring and structural heart, with established invasive and minimally invasive hemodynamic measurement products used in cardiac care. Ventric Health's Vivio competes with Edwards' traditional hemodynamic monitoring franchise by offering a non-invasive alternative for heart failure diagnosis.
• Abbott (CardioMEMS): Abbott's CardioMEMS is an implantable hemodynamic monitor for heart failure management, addressing a similar underlying clinical need (filling pressure measurement) in heart failure patients. Both technologies target LV filling pressure, but Abbott offers an implantable device for chronic management while Ventric Health offers a non-invasive point-of-care diagnostic.
• GE HealthCare: GE HealthCare offers a broad portfolio of cardiac diagnostics including echocardiography and ECG systems used in primary care and cardiology. Ventric Health's COO previously worked at GE Healthcare, and Vivio competes against and complements GE's diagnostic imaging franchise in the cardiology workflow.
• Philips (Cardiac Diagnostics): Philips provides a comprehensive cardiac diagnostics portfolio including ECG, echocardiography, and remote cardiac monitoring used in ambulatory and primary care. Vivio competes for the same primary care diagnostic budget and workflow slot as Philips' cardiac point-of-care devices.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/ventrichealth

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles17 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ventric Health